HealthInvest Partners’s Anika Therapeutics ANIK Stock Holding History

HealthInvest Partners’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$6.18M	Sell	114,600 -400	-0.3%	-$22.1K	13.04%	1
2017 Q3	$6.67M	Sell	115,000 -10,000	-8%	-$523K	7.79%	3
2017 Q2	$6.17M	Sell	125,000 -56,573	-31%	-$2.61M	7.69%	10
2017 Q1	$7.89M	Buy	181,573 +5,606	+3%	+$268K	12.1%	4
2016 Q4	$8.62M	Sell	175,967 -27,526	-14%	-$1.27M	7.94%	2
2016 Q3	$9.74M	Sell	203,493 -209,095	-51%	-$10.3M	7.25%	8
2016 Q2	$22.1M	Sell	412,588 -77,743	-16%	-$3.66M	10.15%	1
2016 Q1	$21.9M	Buy	490,331 +111,586	+29%	+$4.53M	10.27%	1
2015 Q4	$14.5M	Buy	378,745 +337,945	+828%	+$12.9M	6.8%	10
2015 Q3	$1.3M	Buy	+40,800	New	+$1.42M	0.77%	12

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

TAM

THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

HealthInvest Partners's ANIK Position: Q4 2017 in Review

HealthInvest Partners reduced its Anika Therapeutics (ANIK) stake by 0.35% in Q4 2017, selling an estimated $22.1K and leaving 114,600 shares worth $6.18M. The position accounts for 13.04% of the portfolio, ranked #1.

HealthInvest Partners first reported a position in ANIK in Q3 2015 and has held it in 10 quarters since. The position peaked at $22.1M in Q2 2016. 172 funds tracked by Wall St. Rank hold ANIK as of Q4 2017.

HealthInvest Partners held 114,600 shares of Anika Therapeutics worth $6.18M as of Q4 2017.
HealthInvest Partners sold 400 Anika Therapeutics shares in Q4 2017, an estimated $22.1K.
Anika Therapeutics made up 13.04% of HealthInvest Partners's portfolio in Q4 2017, its #1 holding.
HealthInvest Partners first reported a position in Anika Therapeutics in Q3 2015 and has held it in 10 quarters since.
HealthInvest Partners's Anika Therapeutics position peaked at $22.1M in Q2 2016.
172 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2017.

Based on HealthInvest Partners's 13F filing for Q4 2017, filed 9 Feb 2018.